- Home
- CRDL vs NTRB Comparison
CRDL vs NTRB Comparison
Compare CRDL & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- NTRB
- Stock Information
- Founded
- CRDL 2017
- NTRB 2016
- Country
- CRDL Canada
- NTRB United States
- Employees
- CRDL N/A
- NTRB N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- NTRB Industrial Specialties
- Sector
- CRDL Health Care
- NTRB Health Care
- Exchange
- CRDL Nasdaq
- NTRB Nasdaq
- Market Cap
- CRDL 126.5M
- NTRB 94.3M
- IPO Year
- CRDL N/A
- NTRB N/A
- Fundamental
- Price
- CRDL $1.48
- NTRB $7.12
- Analyst Decision
- CRDL Strong Buy
- NTRB Buy
- Analyst Count
- CRDL 2
- NTRB 1
- Target Price
- CRDL $9.00
- NTRB $13.00
- AVG Volume (30 Days)
- CRDL 365.4K
- NTRB 172.5K
- Earning Date
- CRDL 08-11-2025
- NTRB 09-02-2025
- Dividend Yield
- CRDL N/A
- NTRB N/A
- EPS Growth
- CRDL N/A
- NTRB N/A
- EPS
- CRDL N/A
- NTRB N/A
- Revenue
- CRDL N/A
- NTRB $2,398,437.00
- Revenue This Year
- CRDL N/A
- NTRB $560.75
- Revenue Next Year
- CRDL N/A
- NTRB $588.39
- P/E Ratio
- CRDL N/A
- NTRB N/A
- Revenue Growth
- CRDL N/A
- NTRB 18.92
- 52 Week Low
- CRDL $0.77
- NTRB $2.98
- 52 Week High
- CRDL $2.63
- NTRB $9.42
- Technical
- Relative Strength Index (RSI)
- CRDL 57.55
- NTRB 39.52
- Support Level
- CRDL $1.36
- NTRB $8.00
- Resistance Level
- CRDL $1.59
- NTRB $9.21
- Average True Range (ATR)
- CRDL 0.11
- NTRB 0.63
- MACD
- CRDL 0.02
- NTRB -0.16
- Stochastic Oscillator
- CRDL 75.56
- NTRB 17.08
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.